1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

02 Dec 2025
Admin
News Article

SAI Parenterals Acquires 74.6% Stake in Noumed Pharmaceuticals: A Big Leap Toward a Global CDMO Platform

SAI Parenteral’s Limited (SPL) has taken a major step in its global expansion journey. The company announced the acquisition of a 74.6% controlling stake in Adelaide-based Noumed Pharmaceuticals Pty Ltd for Rs. 125 crore. The deal strengthens SPL’s ambition to build a global, innovation-led formulations and CDMO platform.

A Strategic Move Ahead of Its IPO

SPL filed its IPO DRHP with SEBI on September 30, 2025. The offer includes:

A fresh issue worth Rs. 285 crore
An OFS of 3.5 million equity shares
Face value: Rs. 5 per share

This acquisition adds scale and credibility as SPL prepares for public listing.

Why Noumed Matters?

Noumed Pharmaceuticals is a strong player in Australia and New Zealand’s OTC market.

Key highlights:

AUD 60 million revenue
Supplies private-label OTC products to major pharmacy chains
Building a AUD 53 million manufacturing facility in Adelaide
Plant operations expected in Q4 CY 2026
Portfolio includes 451+ product dossiers across multiple therapeutic areas

The acquisition brings SPL deeper access to semi-regulated and regulated markets.

Leadership Voices: What Both Companies See Ahead

A Big Step Toward a Global Formulations and CDMO Platform

Anil KK, Managing Director of SPL, said the deal is transformative.

He highlighted four major synergies:

Combined R&D capabilities
Stronger distribution channels
A deeper dossier library
A modern manufacturing base in Australia

He added that the partnership boosts SPL’s portfolio strength and enhances its entry into regulated markets.

Strengthening Market Reach and Revenue Visibility

According to Anil KK, Noumed’s customer relationships and long-term supply contracts will help SPL improve revenue quality and forecast stability.

Noumed’s View: A Partnership With Momentum

Mark Thulborne, MD of Noumed, welcomed the deal.

He emphasized:

A faster product pipeline
Stronger manufacturing support
Better ability to serve demand in Australia, New Zealand, and global markets

Both leaders view the merger as a long-term value creator.

Backed by Strong Investors

SAI Parenteral’s is supported by:

Samarsh Capital
Vyom Partners
Blue Lotus Capital
Gruhas

This backing strengthens the company’s plans for global expansion.

About SAI Parenterals

SPL is a diversified pharmaceutical formulations company.
It offers integrated services across:

R&D
Regulatory compliance
Manufacturing
Global commercialization

The acquisition moves SPL closer to its goal of becoming a global formulations and CDMO powerhouse.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!